Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. INCR
INCR logo

INCR Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
1.130
Open
1.110
VWAP
1.10
Vol
35.38K
Mkt Cap
62.30M
Low
1.070
Amount
38.81K
EV/EBITDA(TTM)
--
Total Shares
57.15M
EV
284.10M
EV/OCF(TTM)
--
P/S(TTM)
0.50
InterCure Ltd is an Israel-based company primarily enagged in cannabis industry. Thorugh its wholly owned subsidiary Canndoc the Company operates as licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.
Show More

Events Timeline

(ET)
2026-03-03
17:00:00
InterCure Receives Nasdaq Compliance Notice
select
2026-02-19 (ET)
2026-02-19
07:10:00
InterCure Expects Positive EBITDA for 2025
select
2025-11-03 (ET)
2025-11-03
08:38:59
InterCure and Cannasoul Forge Strategic Investment and Collaboration Partnerships
select
2025-10-08 (ET)
2025-10-08
09:03:28
InterCure Announces 1H Revenue of NIS 130M, Up from NIS 126M Last Year
select
2025-09-19 (ET)
2025-09-19
08:51:16
InterCure Reveals Purchase of ISHI for 4.92 Million Common Shares
select
2025-02-12 (ET)
2025-02-12
17:37:10
InterCure names Alexander Rabinovich as Chairman, replacing Ehud Barak
select
2024-12-20 (ET)
2024-12-20
07:36:21
InterCure secures funding to support recovery of Nir Oz facility
select

News

NASDAQ.COM
8.5
06-23NASDAQ.COM
InterCure Secures NIS 22 Million Funding for Growth
  • Funding Scale and Purpose: InterCure has secured NIS 22 million (approximately $7.4 million) through a private placement aimed at supporting the company's recovery, expanding production capacity, and pursuing growth opportunities in regulated medical cannabis markets like Israel and Germany.
  • Investor Background: The financing includes commitments from key shareholders, such as CEO Alexander Rabinovich, along with prominent pharma-focused hedge funds like Bennu Pharma Fund Ltd., indicating strong market confidence in the company.
  • Equity Issuance and Warrants: InterCure will issue 7,895,143 ordinary shares at NIS 2.75 (approximately $0.94) and provide warrants allowing investors to purchase additional shares at NIS 4.125 (approximately $1.41), representing a 53% premium to the reference price.
  • Strategic Significance and Market Reaction: Rabinovich stated that this financing marks a crucial step in the company's recovery and growth strategy, expected to support the expansion of the Nir Oz facility to meet rising demand in Israel and international markets while accelerating global expansion efforts, particularly in Germany.
seekingalpha
8.5
06-22seekingalpha
InterCure Signs Binding Term Sheet for Private Placement
  • Financing Size: InterCure's binding term sheet for private placement initially raises NIS 22 million (approximately $7.4 million), with potential total proceeds reaching NIS 54 million (approximately $18.6 million), indicating strong market appeal.
  • Investor Support: The financing is backed by both existing and new investors, including CEO Alexander Rabinovich and Bennu Pharma Fund, reflecting management's confidence in the company's future growth prospects.
  • Share Issuance: InterCure will issue approximately 7.9 million ordinary shares at NIS 2.75 per share, with investors also receiving warrants to purchase an additional 7.9 million shares at NIS 4.125 per share, representing a roughly 53% premium to the reference closing price.
  • Financing Potential: Should all warrants be exercised for cash, total proceeds from the financing could increase to approximately NIS 54 million, with warrants remaining exercisable for five years, enhancing the company's future financial flexibility.
Newsfilter
8.5
06-15Newsfilter
InterCure Completes First Tranche of Botanico Acquisition Expanding U.S. Market Access
  • Transaction Completion: InterCure has successfully completed the first tranche of its acquisition of Botanico, gaining exclusive access to U.S. genetics and advanced AI technologies, which is expected to significantly enhance its competitiveness in the international medical cannabis market.
  • Market Expansion: This acquisition provides InterCure with a collection of award-winning U.S. cannabis genetics and brands, further solidifying its growth momentum in the German market while laying the groundwork for future expansion in the U.S.
  • Equity Issuance: As part of the transaction, InterCure will issue 2,471,061 ordinary shares and an additional 2,470,073 shares upon satisfaction of the agreement conditions, strengthening its capital structure to support future growth.
  • Strategic Evaluation: InterCure is evaluating opportunities in the regulated U.S. medical cannabis market, with the CEO stating that the acquisition aligns with growth in the German market and changes in the U.S. regulatory landscape, supporting the company's vision of becoming a leading international medical cannabis enterprise.
seekingalpha
9.5
05-01seekingalpha
InterCure Reports Significant FY Revenue Growth
  • Strong Financial Performance: InterCure's fiscal year revenue reached NIS 270.2 million, reflecting significant growth compared to the previous year, indicating the company's robust market performance and business expansion capabilities.
  • Adjusted EBITDA Surge: The adjusted EBITDA of NIS 47 million represents a more than 90% increase from NIS 24 million in 2024, accounting for 17% of total revenue, showcasing the company's enhanced profitability.
  • Reduced Net Loss: The company reported a net loss of NIS 37 million, a substantial decrease from NIS 73 million in 2024, primarily reflecting non-cash provisions related to Bazalet debt and the impact of the ongoing war.
  • Nasdaq Notification: InterCure received a notification from Nasdaq regarding minimum bid requirements, indicating challenges faced in the capital markets, necessitating measures to ensure compliance and maintain investor confidence.
Newsfilter
9.5
04-30Newsfilter
InterCure Reports Strong 2025 Financial Results with Positive Adjusted EBITDA
  • Significant Revenue Growth: InterCure reported over NIS 270 million in revenue for 2025, a 13% increase year-over-year, with NIS 140 million in the second half, reflecting a 24% growth compared to the same period in 2024, indicating strong market recovery.
  • Consistent Positive Adjusted EBITDA: The company achieved an Adjusted EBITDA of NIS 47 million in 2025, over 90% higher than 2024, representing 17% of revenue, marking the twelfth consecutive half-year of positive Adjusted EBITDA, showcasing sustained profitability.
  • Positive Operating Cash Flow: InterCure generated NIS 17 million in positive operating cash flow in 2025, a significant turnaround from a negative cash flow of NIS 67 million in 2024, demonstrating substantial progress in resuming production and sales.
  • Strategic Acquisitions and Partnerships: The company entered into a strategic investment agreement with Cannasoul R&D Ltd., acquiring a 28% stake with plans to increase to 51% within two years, enhancing its research capabilities and supporting its positioning in the U.S. market.
Yahoo Finance
7.0
03-03Yahoo Finance
InterCure Receives Noncompliance Notice from Nasdaq
  • Noncompliance Notice: InterCure received a noncompliance notice from Nasdaq last week, indicating that the company has failed to meet certain listing requirements, which could impact stock trading stability and investor confidence.
  • Potential Consequences: This notice may expose the company to the risk of delisting, affecting its ability to raise funds and its market reputation, especially as investor scrutiny on compliance increases in the current market environment.
  • Response Measures: InterCure must implement effective measures to address the noncompliance issues, including potential financial restructuring or improving corporate governance to ensure adherence to Nasdaq's listing standards.
  • Market Reaction: Investor reactions to this news may lead to stock price volatility, with potential selling pressure in the short term, thereby impacting the company's market capitalization and future financing plans.

Valuation Metrics

The current forward P/E ratio for InterCure Ltd (INCR.O) is 6.18, compared to its 5-year average forward P/E of 0.35. For a more detailed relative valuation and DCF analysis to assess InterCure Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.35
Current PE
6.18
Overvalued PE
2.94
Undervalued PE
-2.24

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.89
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
11.33
Undervalued EV/EBITDA
-13.11

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.22
Current PS
0.00
Overvalued PS
2.08
Undervalued PS
0.36

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

please list me the top moving penny stocks
Intellectia · 65 candidates
Price: $0.10 - $5.00Volume: >= 0Price Change Pct: >= $0.00Relative Vol: >= 1.50Moving Average Relationship: PriceAboveMA5, PriceAboveMA20Week Price Change Pct: >= $0.00Monthly Average Dollar Volume: >= 0
Ticker
Name
Market Cap$
top bottom
EHGO logo
EHGO
Eshallgo Inc
8.21M
GETY logo
GETY
Getty Images Holdings Inc
481.80M
TNON logo
TNON
Tenon Medical Inc
7.19M
SKYQ logo
SKYQ
Sky Quarry Inc
9.11M
CDT logo
CDT
CDT Equity Inc
7.29M
AZTR logo
AZTR
Azitra Inc
3.72M
Gappers stocks
Intellectia · 47 candidates
Region: USRelative Vol: >= 1.50Gap Pattern: GapUp
Ticker
Name
Market Cap$
top bottom
GFAI logo
GFAI
Guardforce AI Co Ltd
16.56M
LSTA logo
LSTA
Lisata Therapeutics Inc
29.60M
PLCE logo
PLCE
Children's Place Inc
92.85M
HUBC logo
HUBC
Hub Cyber Security Ltd
334.74K
IMCC logo
IMCC
IM Cannabis Corp
1.79M
BGLC logo
BGLC
BioNexus Gene Lab Corp
5.61M

Whales Holding INCR

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is InterCure Ltd (INCR) stock price today?

The current price of INCR is 1.09 USD — it has decreased -3.54

What is InterCure Ltd (INCR)'s business?

InterCure Ltd is an Israel-based company primarily enagged in cannabis industry. Thorugh its wholly owned subsidiary Canndoc the Company operates as licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.

What is the price predicton of INCR Stock?

Wall Street analysts forecast INCR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for INCR is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is InterCure Ltd (INCR)'s revenue for the last quarter?

InterCure Ltd revenue for the last quarter amounts to 102.44M USD, increased 7.52

What is InterCure Ltd (INCR)'s earnings per share (EPS) for the last quarter?

InterCure Ltd. EPS for the last quarter amounts to 0.10 USD, decreased -70.59

How many employees does InterCure Ltd (INCR). have?

InterCure Ltd (INCR) has 280 emplpoyees as of July 05 2026.

What is InterCure Ltd (INCR) market cap?

Today INCR has the market capitalization of 62.30M USD.